Ovos Plots Vivimind Cognitive Supplement Launch, Awaits FDA Reply
This article was originally published in The Pink Sheet Daily
Executive Summary
Ovos treads a largely ignored legal pathway for ingredients previously studied as investigational new drugs. A nod from FDA for the ingredient homotaurine in Ovos' product would affirm the pathway and pave the way for other ingredients..